scholarly journals Interleukin-6 Promotes Anti-OspA Borreliacidal Antibody Production In Vitro

2006 ◽  
Vol 13 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Erik L. Munson ◽  
Dean T. Nardelli ◽  
K. H. Kevin Luk ◽  
Monica C. Remington ◽  
Steven M. Callister ◽  
...  
Keyword(s):  
Lymph Node ◽  
B Lymphocytes ◽  
Antibody Production ◽  
Interleukin 6 ◽  
In Vitro Assay ◽  
Vitro Assay ◽  
Lymph Node Cells ◽  
In Vitro Treatment

ABSTRACT Determination of the immunological mediators responsible for promoting the production of borreliacidal antibody may facilitate the development of an improved borreliosis vaccine for human and veterinary use. Previously, we developed an in vitro assay to determine if borreliacidal antibody production could be augmented by treatment with different cytokines. In this study, in vitro treatment of lymph node cells producing borreliacidal antibody with recombinant interleukin-6 (rIL-6) resulted in a fourfold enhancement of anti-OspA borreliacidal antibody. Moreover, rIL-6 enhanced Western immunoblot titers and increased the number of B lymphocytes. In contrast, treatment of anti-OspA borreliacidal antibody-producing cells with anti-IL-6 resulted in a fourfold reduction in borreliacidal activity. Treatment with anti-IL-6 also inhibited enhanced borreliacidal antibody production induced by anti-gamma interferon. These data suggest that IL-6 plays a significant role in the production of anti-OspA borreliacidal antibodies.

Applicability of the OECD 455 in-vitro assay for determination of hERa agonistic activity of isoflavonoids

2020 ◽  
Vol 386 ◽  
pp. 114831 ◽  
Author(s):  
Darja Gramec Skledar ◽  
Václav Tvrdý ◽  
Maša Kenda ◽  
Anamarija Zega ◽  
Milan Pour ◽  
...  
Keyword(s):  
In Vitro Assay ◽  
Vitro Assay ◽  
Agonistic Activity

Spectrophotometric determination of de novo hemozoin/β-hematin formation in an in vitro assay

2004 ◽  
Vol 325 (1) ◽  
pp. 85-91 ◽  
Author(s):  
Abhai K Tripathi ◽  
Shabana I Khan ◽  
Larry A Walker ◽  
Babu L Tekwani
Keyword(s):  
Spectrophotometric Determination ◽  
De Novo ◽  
In Vitro Assay ◽  
Vitro Assay

scholarly journals Interleukin-6 Enhances Production of Anti-OspC Immunoglobulin G2b Borreliacidal Antibody

2001 ◽  
Vol 69 (7) ◽  
pp. 4268-4275 ◽  
Author(s):  
Monica C. Remington ◽  
Erik L. Munson ◽  
Steven M. Callister ◽  
Melanie L. Molitor ◽  
John A. Christopherson ◽  
...  
Keyword(s):  
Lymph Node ◽  
Antibody Production ◽  
Interleukin 6 ◽  
Vaccine Development ◽  
Surface Protein ◽  
Whole Cells ◽  
Lymph Node Cells ◽  
Potential Vaccine ◽  
High Level ◽  
Protection Against Infection

ABSTRACT Protection against infection with Borrelia burgdorferiis dependent primarily on induction of complement-dependent antibody that can kill the spirochete. Measuring the production of sustained high levels of borreliacidal antibody is thus paramount for determining potential vaccine efficacy. We investigated the borreliacidal antibody response in sera and the amount of antibody produced by cultured lymph node cells of C3H/HeJ mice vaccinated with outer surface protein C (OspC). We showed that recombinant OspC was a weak stimulant of borreliacidal antibody production compared to whole cells of OspC-expressing B. burgdorferi. Mice vaccinated withB. burgdorferi in adjuvant produced a high level (titer, 5,120) of anti-OspC borreliacidal antibody, which waned rapidly. Similarly, borreliacidal antibody production by cultured lymph node cells from vaccinated mice peaked soon after vaccination and then decreased. Treatment of lymph node cells with interleukin-6 (IL-6) augmented borreliacidal antibody production, particularly immunoglobulin G2b, whereas treatment with anti-IL-6 inhibited the borreliacidal response. These findings demonstrate a previously unrecognized role for IL-6 in borreliacidal antibody production that may have important implications for vaccine development.

Use of an in Vitro Assay for Determination of Biofilm-Forming Capacity of Bacteria in Chronic Rhinosinusitis

2006 ◽  
Vol 20 (5) ◽  
pp. 434-438 ◽  
Author(s):  
Zohra Bendouah ◽  
Jean Barbeau ◽  
Walid Abou Hamad ◽  
Martin Desrosiers
Keyword(s):  
Chronic Rhinosinusitis ◽  
In Vitro Assay ◽  
Vitro Assay

scholarly journals Development of a Novel In Vitro Assay (ALS Assay) for Evaluation of Vaccine-Induced Antibody Secretion from Circulating Mucosal Lymphocytes

2001 ◽  
Vol 8 (3) ◽  
pp. 482-488 ◽  
Author(s):  
H. Sunny Chang ◽  
David A. Sack
Keyword(s):  
Tissue Culture ◽  
Antibody Production ◽  
Specific Antibody ◽  
In Vitro Assay ◽  
Cholera Vaccine ◽  
Oral Vaccination ◽  
Vitro Assay ◽  
Antigen Stimulation ◽  
Antibody Secretion

ABSTRACT We describe here a novel method for measuring in vitro antibody secretion from the tissue culture of human B lymphocytes in peripheral blood mononuclear cells (PBMC) after oral vaccination with a killed cholera vaccine. Enzyme-linked immunosorbent assay (ELISA) titers of the antibody secreted in the cell supernatant were determined. The validation results demonstrated that human PBMC remained viable and continued to secrete antibodies (total immunoglobulin A [IgA] and IgG) for up to 4 days of incubation at 37°C with 5% CO2in cell cultures. The secreted antibody concentration correlated positively with the PBMC concentration and incubation time in the tissue culture and correlated negatively with the storage time of the whole blood at room temperature. In vitro assay of secreting antibody in the lymphocyte supernatant (i.e., the ALS assay) is capable of the detecting specific antibody response after oral vaccination with a killed whole-cell-plus-B-subunit cholera vaccine (WC-B) in healthy adults in a phase I clinical trial. Postimmunization PBMC secreted antibodies to cholera toxin in the cell supernatants. Antibody production did not require any in vitro antigen stimulation. In the ALS assay, antigen-specific antibody titers of prevaccination samples were barely detectable, whereas serum antitoxin ELISA titers in background of prevaccine samples were significantly higher than the ALS titers. We conclude that, without any in vitro antigen stimulation after vaccination, PBMC secrete antibodies into the supernatants in the ALS assay. This assay can quantitatively measure the antigen-specific antibody production from the PBMC culture in postvaccination blood samples.

Sign in / Sign up

Export Citation Format

Share Document